|
Drugs that tweak your DNA to eliminate hunger FOR GOOD and retain every ounce of muscle... top obesity expert reveals the dozens of 'Ozempic 2.0 meds' being developed to cash in on obesity gold rush
[DM] Look for Military grade products to increase muscle mass/endurance/oxygenation.Blockbuster drugs like Ozempic and Wegovy revolutionized the weight-loss world. Experts estimate that the drugs alone will raise the US GDP by $360billion, by making workers more productive and healthy. And despite growing evidence of lasting side effects like diarrhea, stomach paralysis, and suicidal thoughts, the growth continues. Weight-loss experts are now predicting what Ozempic and Wegovy's next chapter will look like, such as the drugs being available as cheaper pills or genetic altering that eliminates the need for medications altogether. Speaking this week at a health conference hosted by the Wall Street Journal in Boston, Dr Florencia Halperin, an endocrinologist and chief medical officer at Form Health, said that there's a 'tremendous pipeline of drugs' in development that could streamline or even eventually replace Ozempic. Currently, Ozempic and Wegovy use the active ingredient semaglutide to mimic the production of glucagon-like peptide 1 (GLP-1), a protein that triggers hormones in the brain to tell the stomach that it's full. 'We've known about GLP-1, a hormone that intestinal cells make, since the 1980s, and that has kind of paved the way for the development of GLP-1 receptor agonist drugs,' she told DailyMail.com. 'But weight regulation is very complex, and GLP-1 is not the only pathway that controls weight regulation. There are other sort of opportunities to develop drugs and other targets.' However, there are risks with targeting certain hormones, as they can lead to a variety of bizarre side effects. For example, some patients have reported less desire to drink alcohol or gamble. While upcoming treatments are in various stages of testing, Dr Halperin said that options like oral GLP-1 agonists and those that target other hormones could hit the market in a short amount of time. 'I can guess as early as next year,' she said. However, she noted that more extensive treatments, such as gene editing, could take several years to become available to the public. She estimates that at least 70 treatments are in development. GLP-1 agonists have are already starting to evolve quickly, with the newest injection, Zepbound, being approved by the Food and Drug Administration (FDA) in November. The medication contains the active ingredient tirzepatide, which is also found in Mounjaro. Not only does it target GLP-1, but also the hormone glucose-dependent insulinotropic polypeptide (GIP), which experts believe might also improve how the body breaks down sugar and fat, alongside dampening appetite. Posted by: Skidmark 2024-02-25 |
| http://www.rantburg.com/poparticle.php?ID=692152 |